Alexander Rivkin MD Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$92,150	10
2024	Research	$141,141	9
2023	Research	$200,500	15
2022	Research	$1,049,890	32
2021	Research	$19,077	5
2020	Research	$169,700	17
2019	Research	$136,937	17

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,492,907 68 payments
Allergan Inc. $315,987 36 payments
Endo Pharmaceuticals Inc. $500 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $658,294 11 payments
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $408,364 13 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $168,002 13 payments
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $141,804 18 payments
BOTOX (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double Blind, Multi-Dose, Placebo-Controlled Study $105,998 8 payments
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition $102,620 16 payments
BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 2b, Multicenter, Randomized, Double Blind, Multi-Dose, Placebo-Controlled Study $78,030 7 payments
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $38,346 3 payments
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study across approximately 35 sites in USA, Belgium, Canada, Germany, Russia, and the UK. $20,681 2 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $16,220 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.